In Studies of Medtronic Stents, Patients Who Interrupted Dual Antiplatelet Therapy Early Saw No Increased Thrombosis Risk – Medtronic Inc. (NYSE:MDT)

[Thomson Reuters ONE] – New Data Presented at TCT and Published by JAMA Affirms Excellent Safety Profile of Zotarolimus-Eluting Stents SAN FRANCISCO — Oct. 31, 2013 — According to findings from several studies . . . → Read More: In Studies of Medtronic Stents, Patients Who Interrupted Dual Antiplatelet Therapy Early Saw No Increased Thrombosis Risk – Medtronic Inc. (NYSE:MDT) Similar posts: Company Update: Medtronic Inc. (NYSE:MDT) – Medtronic Presents Three-Year Results From SYMPLICITY HTN-2 Showing Significant and Sustained Drops in Blood Pressure After Treatment with the Symplicity(TM) Renal Denervation System [Thomson Reuters ONE] – Longest-term data from the first... Stock Update: Medtronic Inc. (NYSE:MDT) – Medtronic: It Might Be Too Late To Jump On The Momentum Bandwagon [at Seeking Alpha] – Shares of Medtronic ( MDT... Earnings for Biogen Projected to Rise – Biogen Idec Inc. (NASDAQ:BIIB) [at Forbes] – Wall Street is expecting higher profit...